$INMB
Inmune Bio, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024092861 Filed on October 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.219M
YoY Change -14.32%
% of Gross Profit
Research & Development $10.07M
YoY Change 68.2%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $12.29M
YoY Change 43.34%
Operating Profit -$12.29M
YoY Change 44.07%
Interest Expense $145.0K
YoY Change -125.44%
% of Operating Profit
Other Income/Expense, Net $193.0K
YoY Change 451.43%
Pretax Income -$12.09M
YoY Change 41.27%
Income Tax
% Of Pretax Income
Net Earnings -$12.09M
YoY Change 41.22%
Net Earnings / Revenue
Basic Earnings Per Share -$0.60
Diluted Earnings Per Share -$0.60
COMMON SHARES
Basic Shares Outstanding 22.17M shares 19.78M shares
Diluted Shares Outstanding 20.19M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.55M
YoY Change -19.73%
Cash & Equivalents $33.55M
Short-Term Investments
Other Short-Term Assets $879.0K
YoY Change -41.4%
Inventory
Prepaid Expenses
Receivables $1.109M
Other Receivables $311.0K
Total Short-Term Assets $35.85M
YoY Change -21.4%
LONG-TERM ASSETS
Property, Plant & Equipment $335.0K
YoY Change -16.25%
Goodwill
YoY Change
Intangibles $16.51M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $82.00K
YoY Change -36.43%
Total Long-Term Assets $16.93M
YoY Change -0.91%
TOTAL ASSETS
Total Short-Term Assets $35.85M
Total Long-Term Assets $16.93M
Total Assets $52.78M
YoY Change -15.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.65M
YoY Change 180.13%
Accrued Expenses $135.0K
YoY Change 35.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $2.494M
YoY Change -75.06%
Total Short-Term Liabilities $13.82M
YoY Change -3.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $284.0K
YoY Change -76.33%
Total Long-Term Liabilities $284.0K
YoY Change -92.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.82M
Total Long-Term Liabilities $284.0K
Total Liabilities $14.11M
YoY Change -21.48%
SHAREHOLDERS EQUITY
Retained Earnings -$153.9M
YoY Change 36.65%
Common Stock $22.00K
YoY Change 22.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.68M
YoY Change
Total Liabilities & Shareholders Equity $52.78M
YoY Change -15.82%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$12.09M
YoY Change 41.22%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.986M
YoY Change 63.99%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.792M
YoY Change -666.01%
NET CHANGE
Cash From Operating Activities -6.986M
Cash From Investing Activities
Cash From Financing Activities 9.792M
Net Change In Cash 2.806M
YoY Change -146.84%
FREE CASH FLOW
Cash From Operating Activities -$6.986M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5205835
dei Trading Symbol
TradingSymbol
INMB
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38793
dei Entity Registrant Name
EntityRegistrantName
INMUNE BIO INC.
dei Entity Address Address Line1
EntityAddressAddressLine1
225 NE Mizner Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 640
dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33432
dei City Area Code
CityAreaCode
(858)
dei Local Phone Number
LocalPhoneNumber
964-3720
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22172451 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33552000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35848000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1109000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1905000 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
311000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
537000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
864000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1510000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
35851000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
39942000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
335000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
414000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16514000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16514000 usd
CY2024Q3 us-gaap Assets
Assets
52782000 usd
CY2023Q4 us-gaap Assets
Assets
57001000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10590000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7901000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
549000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
489000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2494000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9921000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
135000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
119000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13823000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18465000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
397000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
14107000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
18862000 usd
CY2024Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
75697 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
75697 shares
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
799000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22172451 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22172451 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17950776 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17950776 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
22000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193575000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
159143000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1036000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-799000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153886000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121022000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
38675000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
37340000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52782000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57001000 usd
CY2023Q3 us-gaap Revenues
Revenues
43000 usd
us-gaap Revenues
Revenues
14000 usd
us-gaap Revenues
Revenues
127000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2219000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2586000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7369000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7223000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10067000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5985000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25813000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14266000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
12286000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8571000 usd
us-gaap Operating Expenses
OperatingExpenses
33182000 usd
us-gaap Operating Expenses
OperatingExpenses
21489000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12286000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8528000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-33168000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-21362000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
193000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
304000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-238000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12093000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8563000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32864000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21600000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.2
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20185676 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20185676 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18008295 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18008295 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19176853 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19176853 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17966990 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17966990 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12093000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8563000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32864000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21600000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-323000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-23000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-237000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-36000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12416000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8586000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33101000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21636000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
37340000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1779000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
130000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11025000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
28224000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2350000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2032000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
13465000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-44000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-9746000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
36281000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1719000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
12292000 usd
CY2024Q3 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
799000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-323000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12093000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
38675000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
60104000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1737000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6536000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
55296000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1863000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6501000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
50654000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
775000 usd
CY2023Q3 inmb Stock Redeemed Or Called During Period Value Reclassification To Redeemable Common Stock
StockRedeemedOrCalledDuringPeriodValueReclassificationToRedeemableCommonStock
-799000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1889000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-23000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8563000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
43933000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32864000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21600000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5848000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5489000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
73000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
179000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-796000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6012000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-226000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-186000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-646000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2492000 usd
inmb Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
-127000 usd
inmb Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
-34000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-49000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
30000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2689000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1531000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
20000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
70000 usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
60000 usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-120000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
254000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-18000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-14000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22348000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8579000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
27789000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
775000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
7500000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
2500000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20289000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1725000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-237000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-36000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2296000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10340000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35848000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52153000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33552000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41813000 usd
us-gaap Interest Paid Net
InterestPaidNet
661000 usd
us-gaap Interest Paid Net
InterestPaidNet
1394000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32900000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22300000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preparing financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions.</p>
CY2024Q3 us-gaap Other Receivables
OtherReceivables
545000 usd
CY2024Q3 inmb Vendor Payable Term
VendorPayableTerm
P2Y
CY2024Q3 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.02 pure
CY2024Q3 us-gaap Investment Interest Rate
InvestmentInterestRate
0.10 pure
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
545000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10241045 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5575074 shares
us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1109000 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1905000 usd
inmb Net Sales Percentage
NetSalesPercentage
0.05 pure
CY2024Q3 inmb Percentage Of Licensor Royalty Patent Grant
PercentageOfLicensorRoyaltyPatentGrant
0.01 pure
inmb Percentage Of Net Sales To Pay Royalties
PercentageOfNetSalesToPayRoyalties
0.025 pure
inmb Agreement Expiration Term
AgreementExpirationTerm
The PITT Agreement expires upon the earlier of: (i) expiration of the last claim of the Patent Rights (as defined in the PITT Agreement) forming the subject matter of the PITT Agreement; or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
335000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
414000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
135000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
119000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
397000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
419000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
516000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
15000000 usd
CY2024Q3 us-gaap Secured Debt
SecuredDebt
2500000 usd
CY2024Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2494000 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
145000 usd
us-gaap Interest Expense
InterestExpense
752000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
568000 usd
us-gaap Interest Expense
InterestExpense
1811000 usd
inmb Prepayment Of Premium Percentage
PrepaymentOfPremiumPercentage
0.01 pure
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
9100000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
0.0341 pure
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
0.0497 pure
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77 pure
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd
CY2024Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4800000 usd
CY2024Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
4500000 usd
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.152
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3000000 usd
CY2021Q1 us-gaap Common Unit Issuance Value
CommonUnitIssuanceValue
45000000 usd
CY2023Q3 inmb Percentage Of Commission
PercentageOfCommission
0.03 pure
CY2024Q3 inmb Aggregate Offering Price Amount
AggregateOfferingPriceAmount
75000000 usd
CY2024Q3 inmb Percentage Of Gross Proceeds
PercentageOfGrossProceeds
0.03 pure
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
300000 usd
CY2024Q3 us-gaap Common Unit Issuance Value
CommonUnitIssuanceValue
74700000 usd
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
75697 shares
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10.56
CY2023Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
775000 usd
CY2023Q4 us-gaap Temporary Equity Share Subscriptions
TemporaryEquityShareSubscriptions
75697 shares
CY2023Q4 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
799000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5496000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.73
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21509000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
832307 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.79
inmb Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Terms
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerms
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
31500 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.35
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6296807 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2531000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5032843 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M8D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2531000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1700000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5800000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1900000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5500000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9100000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M29D
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
45386 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1719000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1889000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5848000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5489000 usd
CY2020Q3 us-gaap Grants Receivable
GrantsReceivable
2900000 usd
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
47000 usd
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
192000 usd
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
198000 usd
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
51000 usd
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
488000 usd
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
69000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
419000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
135000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
40000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
120000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
41000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
123000 usd
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
1200000 usd
CY2024Q3 us-gaap Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
200000 usd
CY2024Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
1000000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 inmb Non Rule10b51 Arr Modified Flag
NonRule10b51ArrModifiedFlag
false
CY2024Q3 inmb Rule10b51 Arr Modified Flag
Rule10b51ArrModifiedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
usd
CY2024Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
shares
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Revenues
Revenues
usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
CY2024Q3 inmb Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Options Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueOptionsCancelled
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001711754

Files In Submission

Name View Source Status
0001213900-24-092861-index-headers.html Edgar Link pending
0001213900-24-092861-index.html Edgar Link pending
0001213900-24-092861.txt Edgar Link pending
0001213900-24-092861-xbrl.zip Edgar Link pending
ea0217646-10q_inmune.htm Edgar Link pending
ea021764601ex31-1_inmune.htm Edgar Link pending
ea021764601ex31-2_inmune.htm Edgar Link pending
ea021764601ex32-1_inmune.htm Edgar Link pending
ea021764601ex32-2_inmune.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inmb-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
inmb-20240930_cal.xml Edgar Link unprocessable
inmb-20240930_def.xml Edgar Link unprocessable
inmb-20240930_lab.xml Edgar Link unprocessable
inmb-20240930_pre.xml Edgar Link unprocessable
ea0217646-10q_inmune_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable